Introduction
Gastric cancer is the second leading cause of cancerrelated death worldwide, accounting for more than 20 deaths per 100 000 population annually in East Asia, Eastern Europe, and parts of Central and South America [1] . Gastric cancer is also the second most frequent cause of cancer death after lung cancer in Japan (despite the markedly higher curability obtained by early detection and surgery than in Western countries), because unresectable or recurrent gastric cancer shows a poor prognosis. The development of effective standard chemotherapy is warranted.
For unresectable or recurrent gastric cancer, several phase III trials have demonstrated that a 5-fl uorouracil (5-FU)-based regimen provides a survival benefi t to these patients over best supportive care [2] [3] [4] . Although quite a few randomized trials [5] [6] [7] [8] [9] [10] [11] [12] , using anthracyclin, mitomycin C (MMC), 5-FU, methotrexate (MTX), and cisplatin (CDDP), were carried out before the early 1990s, none of the chemotherapy regimens showed a survival benefi t over 5-FU alone, and no worldwide consensus about a standard regimen has been obtained. For two decades, the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group (GIOSG/ JCOG) has conducted several clinical trials to establish standard chemotherapy (Table 1) .
investigated. In a randomized phase II study (JCOG 8501) comparing FT plus MMC (FTM) with UFT plus MMC (UFTM) [13] , UFTM showed a higher response rate than FTM. It was concluded that UFTM would be a candidate for a test arm in a future phase III trial.
Subsequently, the GIOSG/JCOG introduced Western chemotherapy regimens such as etoposide plus doxorubicin plus CDDP (EAP) [14] and 5-FU plus CDDP (FP) [15] . Although a high response rate and a 5-year survival of 10% were obtained in the EAP trial, treatmentrelated deaths occurred in 10% of the patients. While the dose and schedule of FP in Japan were slightly modifi ed from those in Western trials [12] , the FP trial [15] showed a response rate and survival similar to those of Western trials. Therefore, the FP regimen was selected for a future phase III trial.
When the GIOSG/JCOG was planning a randomized phase III trial (JCOG 9205) [16] , it was reported that, in a Western phase III trial [9] , combination chemotherapy consisting of 5-FU, doxorubicin, and MMC (FAM) did not show a survival benefi t over 5-FU alone Therefore, the GIOSG/JCOG decided to adopt 5-FU alone for the control arm in that trial, which was conducted as a three-arm phase III trial comparing FP and UFTM with 5-FU alone. FP did not show signifi cantly longer survival despite its higher response rate and longer progression-free survival; this was associated with more severe toxicities than 5-FU alone. Furthermore, UFTM resulted in the worst survival among the three treatment arms and showed more severe toxicities than 5-FU alone. JCOG 9205 concluded that 5-FU alone would remain as the control arm for a subsequent phase III study. Although no survival benefi t of combination chemotherapy containing 5-FU and CDDP over 5-FU alone has been confi rmed in several phase III trials [8, 9, 12] , the FP regimen has been the one most widely used for unresectable and recurrent gastric cancer all over the world.
JCOG 9912
In the late 1990s, some new antitumor agents were developed for gastric cancer in Japan. Combination chemotherapy of irinotecan (CPT-11) plus CDDP showed a response rate of 59% and a median survival time of 322 days, associated with grade 4 neutropenia (57%), and grade 3 or 4 diarrhea (20%) [17] . S-1, a new oral fl uoropyrimidine, consisting of FT, 5-chloro-2, 4-dihydropyrimidine, and potassium oxonate, showed a response rate of 45% and a high 2-year survival rate of 17% in a total of 100 patients in two phase II studies, associated with low incidences of grade 3 or 4 toxicities [18, 19] . These results seemed very promising, and both a combination of CPT-11 plus CDDP and monotherapy with S-1 were adopted for test arms. The GIOSG/JCOG then planned a three-arm phase III study (JCOG 9912) to investigate the superiority of CPT-11 plus CDDP and the non-inferiority of S-1 compared to continuous infusion of 5-FU [20] (Fig. 1) . The primary endpoint was overall survival, and secondary endpoints were time to treatment failure, nonhospitalized survival, adverse events, and response rate.
While the eligibility criteria of JCOG 9912 were similar to those of other recent phase III studies, the specifi c points of JCOG 9912 were that the presence of measurable lesions according to Response Evaluation Criteria in Solid Tumors (RECIST) was not mandatory and that patients with severe peritoneal metastasis were [14] II A phase II study of EAP (etoposide, adriamycin, and cisplatin) in patients with advanced gastric cancer 9001 [15] II Phase II study of protracted infusional 5-fl uorouracil combined with cisplatin for advanced gastric cancer 9205 [16] III Randomized phase III trial of fl uorouracil alone versus fl uorouracil plus cisplatin versus uracil and tegafur plus mitomycin C in patients with unresectable advanced gastric cancer 9207 [28] II A phase II study of sequential methotrexate and 5-fl uorouracil chemotherapy in patients with previously treated gastric cancer 9410 [29] II A phase II study of doxifl uridine in elderly patients with advanced gastric cancer 9603 [23] II A phase II study of sequential methotrexate and 5-fl uorouracil for advanced gastric cancer with malignant ascites 9912 [20] III Table 2 summarizes the toxicities in JCOG 9912. Leucopenia and neutropenia were the most severe toxicities, and grade 3 or 4 hyponatremia, fatigue, anorexia, diarrhea, and nausea were most frequently observed in the CPT-11 plus CDDP arm. Only diarrhea was more severe in the S-1 arm than in the 5-FU arm, while there were no remarkable differences in the incidences of other toxicities between the S-1 arm and the 5-FU arm. It was considered that monotherapy with S-1 was feasible. Table 3 summarizes the results for the effi cacy of JCOG 9912. The response rate of the CPT-11 plus CDDP arm was 38%, and those of the S-1 and 5-FU arms were 28% and 9%. The median progression-free survival time of the 5-FU arm was 2.9 months; that of the CPT-11 plus CDDP arm, 4.8 months; and that of the S-1 arm, 4.2 months. Thus, it can be said that the antitumor effect of CPT-11 plus CDDP was the best among the three treatment arms. The median time to treatment failure of the 5-FU arm was 2.3 months; CPT-11 plus CDDP arm, 3.7 months; and the S-1 arm, 4.0 months. As for the reasons for treatment failure, more than 85% of the patients stopped treatment due to disease progression in the 5-FU arm and S-1 arm, while more than 30% of the patients stopped treatment for reasons related to toxicities in the CPT-11 plus CDDP arm. Substantial toxicities seemed to shorten the time to treatment failure in the CPT-11 plus CDDP arm.
As for the overall survival, the CPT-11 plus CDDP arm showed the best survival until 1 year, and the median survival times (MSTs) of the 5-FU, CPT-11 plus CDDP, and S-1 arms were 10.8, 12.3, and 11.4 months, while the S-1 arm showed the best survival after 1 year. As a whole, the hazard ratio to 5-FU of CPT-11 plus CDDP was 0.85 (95% confi dence interval [CI], 0.70-1.04; P = 0.055) and that of S-1 was 0.83 (95% CI, 0.68-1.01; P = 0.034 for superiority, P < 0.001 for noninferiority). Because the signifi cance level for superiority after confi rming the non-inferiority of S-1 was pre-specifi ed to be 0.025, it was concluded that only the non-inferiority of S-1 was shown to be statistically signifi cant, while there was no consensus about the signifi cance level, 0.025 or 0.05, for superiority after confi rming non-inferiority.
Because infusion chemotherapy is commonly performed with hospitalization in Japan, it is considered that the non-hospitalized survival refl ects a patient's benefi t from the quality-of-life point of view. Both the CPT-11 plus CDDP and S-1 arms showed longer nonhospitalized survival compared to the 5-FU arm.
S-1 showed a higher response rate, longer progression-free survival, and longer non-hospitalized survival than 5-FU, associated with feasible toxicities. It can be said that S-1 may be superior to 5-FU in practice.
In conclusion, S-1 should be considered as standard chemotherapy for unresectable or recurrent gastric cancer.
Other phase III trials
There have been two other randomized phase III trials with S-1 as a control arm. One investigated the superiority of S-1 plus CDDP compared with S-1 alone in regard to overall survival S-1 plus cisplatin vs S-1 in RCT in the treatment for stomach cancer (SPIRITS trial) [21] . Overall survival was signifi cantly longer in the S-1 plus CDDP arm (MST, 13.0 months) than in the S-1 arm (MST, 11.0 months; P = 0.04). The other phase III trial compared the combination of S-1 plus CPT-11 with S-1 (GC 0301/TOP 002) [22] . Although the MST of the S-1 arm was 10.5 months and that of the S-1 plus CPT-11 arm was 12.8 months, S-1 plus CPT-11 did not show signifi cant superiority (P = 0.23). The treatment results for the S-1 arm, in terms of response rates and overall survival, were very similar in the three phase III trials (Table 4) . Generally, it is recognized that S-1 plus CDDP is the standard treatment for unresectable or recurrent gastric cancer in Japan. Of note, there are two global trials investigating the non-inferiority of oxaliplatin and/or oral pyrimidine (capecitabine) compared to CDDP and continuous infusion of 5-FU; both of these 11.4 -P = 0.055* P = 0.034* P < 0.001** P compared with 5-FU: *P value for superiority; **P value for non-inferiority PFS, progression-free survival; TTF, time to treatment failure trials have met their primary endpoints. It can be said that Japan and Western countries share a consensus on standard chemotherapy with oral fl uoropyrimidine plus platinum for advanced gastric cancer. However, strictly speaking, none of the combination chemotherapies with oral fl uoropyrimidine and platinum have shown superiority to FP, while S-1 monotherapy showed a response rate and progression-free survival similar to those of FP in the JCOG 9205 trial [16] as results of fi rst-line chemotherapy. Of note, because the fi nal analysis of JCOG 9912 [20] was performed just 1 year after the last patient enrollment, approximately 15% of the patients were censored in the survival curves after 1 year. Therefore, the long-term results of JCOG 9912 have not been obtained yet. While there was a remarkable difference in long-term survival between the arms in the SPIRITS trial (2-year survival rate: S-1, 15.3%; S-1 + CDDP, 23.6%), the 2-year survival rate of the S-1 arm in JCOG 9912 is speculated to be more than 20% from the survival curve at the fi nal analysis. Therefore, it might be considered that it has not yet been clarifi ed which is the better treatment strategy, i.e., whether monotherapy with S-1 followed by subsequent chemotherapy, or intensive combination chemotherapy such as S-1 plus CDDP as the fi rst-line treatment will have a greater impact on long-term survival. The superiority of S-1 plus CDDP combination chemotherapy to FP is now under investigation by the First-Line Advanced Gastric Cancer Study (FLAGS) trial to confi rm whether S-1 plus CDDP can be a standard chemotherapy all over the world.
JCOG 0106
The peritoneum, as well as liver and lymph nodes, is a major common metastatic site. The incidence of peritoneal metastasis in patients with unresectable or recurrent gastric cancer is higher than 50%. The prognosis of patients with severe peritoneal metastasis is considered to be poor, because it causes various kinds of complications such as ascites, bowel obstruction, and hydronephrosis, causing deterioration of the patient's general condition; also, these patients usually do not have target lesions according to RECIST. For these reasons, patients with severe peritoneal metastasis are generally excluded from clinical trials. Moreover, new drugs such as CPT-11 and S-1 cannot be used for these patients; the impaired bowel passage caused by severe peritoneal metastasis causes severe CPT-11 toxicities through the reabsorption of its active metabolite SN-38, and the impairment also prevents the oral administration of S-1. These patients were also excluded from the recent Japanese phase III trials. Therefore, evidence from clinical trials cannot be applied to these patients, and it is considered that a standard chemotherapy for gastric cancer patients with severe peritoneal metastasis has not been established.
The GIOSG/JCOG has decided to use different treatment strategies according to the presence or absence of severe peritoneal metastasis, and planned a phase III trial (JCOG 0106) targeting patients with severe peritoneal metastasis (Fig. 2) . In this trial, 5-FU alone was adopted as the control arm, from the results of JCOG 9205, because it was the least toxic and could be applied safely to patients with severe peritoneal metastasis. Sequential therapy of 5-FU and MTX with leucovorin rescue (MTX/5-FU) was adopted as the test arm in this trial, based on the results of a phase II study of this regimen (JCOG 9603 [23] ), targeting severe peritoneal metastasis; massive ascites was markedly decreased in 13 out of 37 patients (35%). The MTX/5-FU regimen is based on biochemical modulation; it is reported that an increase of phosphoribosyl pyrophosphate in cancer cells through the inhibition of purine synthesis by MTX enhances the effects of 5-FU. The major toxicities with this sequential therapy in the JCOG 9603 trial were leucopenia, anemia, 
JCOG 0407
The survival benefi t of second-line chemotherapy for unresectable or recurrent gastric cancer has not been confi rmed by randomized phase III trials. In a comparison of the overall survival of patients receiving 5-FU as fi rst-line treatment between the JCOG 9205 trial [16] and the JCOG 9912 trial [20] , the MST in the JCOG 9912 trial was markedly longer than that in the JCOG 9205 trial. Between the time of the JCOG 9205 trial and the JCOG 9912 trial, new drugs such as CPT-11, paclitaxel [24] , and docetaxel [25] were approved in Japan, and they were widely used as second-line treatment in clinical practice [26, 27] . While around half of the patients in the JCOG 9205 trial received second-line chemotherapy, more than 70% of the patients in the JCOG 9912 trial received this treatment. It is considered that second-line chemotherapy may contribute to prolongation of survival. At present, several randomized phase III trials of second-line treatment after the failure of fi rst-line treatment with fl uoropyrimidine and/or platinum are underway in Japan.
Although not a few patients are complicated with severe peritoneal metastasis after the failure of fi rst-line chemotherapy, second-line chemotherapy is limited because of the patients' poor condition. Because a standard second-line chemotherapy for severe peritoneal metastasis has not been established, it is diffi cult to decide on the control arm for a randomized trial. From our experience in clinical practice, we believe there are two candidates for treatment arms in such clinical trials. One is the "best available fl uoropyrimidine", which is based on a mechanism of cytotoxicity that is different from that of 5-FU; this is achieved through the use of different administration methods from the initial therapy; such as continuous infusion (oral agent) and bolus infusion, with and without biochemical modulation by leucovorin or MTX. The other candidate treatment arm is the weekly administration of paclitaxel, which showed a response rate of around 20%, with fewer toxicities than for tri-weekly administration, even as second-line treatment; also with weekly treatment, a high concentration was maintained in ascites. Thus, the GIOSG/JCOG has started a randomized phase II trial (Fig. 3) in patients with severe peritoneal metastasis, comparing best available 5-FU with weekly administration of paclitaxel as second-line chemotherapy after the failure of fi rst-line chemotherapy containing fl uoropyrimidine, and patient accrual is under way.
Conclusion
In this article, GIOSG/JCOG clinical trials have been reviewed. There have been many phase III clinical trials in Japan and all over the world. The progress of chemotherapy for unresectable and recurrent gastric has been remarkable since the late 1990s, and standard chemotherapy has been established. In the near future, revolutionary progress can be expected through the development of new drugs, including molecular targeting agents. 
